Cyclacel Pharmaceuticals - CYCC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 1,249.21 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.26
▲ +0.02 (1.61%)

This chart shows the closing price for CYCC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cyclacel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYCC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYCC

Analyst Price Target is $17.00
▲ +1,249.21% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cyclacel Pharmaceuticals in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 1,249.21% upside from the last price of $1.26.

This chart shows the closing price for CYCC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Cyclacel Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/18/2022OppenheimerReiterated RatingOutperform$17.00Low
11/18/2021LADENBURG THALM/SH SHLower TargetBuy$18.00 ➝ $17.00High
4/29/2021OppenheimerInitiated CoverageOutperform$17.00High
5/21/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00High
5/21/2020Roth CapitalReiterated RatingBuy$24.00High
5/19/2020Brookline Capital ManagementInitiated CoverageBuy$22.00High
5/12/2020Roth CapitalReiterated RatingBuyLow
5/23/2019Roth CapitalReiterated RatingBuyLow
5/15/2019HC WainwrightReiterated RatingBuyLow
10/4/2018Roth CapitalSet TargetBuy$160.00Low
9/7/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$125.00Medium
9/5/2018Roth CapitalInitiated CoverageBuy$160.00High
8/10/2018HC WainwrightSet TargetBuy$140.00Medium
3/29/2018HC WainwrightReiterated RatingBuyHigh
(Data available from 9/27/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/30/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Read More

Today's Range

Now: $1.26
Low: $1.23
High: $1.32

50 Day Range

MA: $1.47
Low: $1.10
High: $2.01

52 Week Range

Now: $1.26
Low: $1.01
High: $6.10

Volume

51,391 shs

Average Volume

492,791 shs

Market Capitalization

$15.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Cyclacel Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Cyclacel Pharmaceuticals in the last year: LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for CYCC.

What is the current price target for Cyclacel Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Cyclacel Pharmaceuticals in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 1,249.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting CYCC will reach $17.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $17.00 for Cyclacel Pharmaceuticals in the next year.
View the latest price targets for CYCC.

What is the current consensus analyst rating for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYCC will outperform the market and that investors should add to their positions of Cyclacel Pharmaceuticals.
View the latest ratings for CYCC.

What other companies compete with Cyclacel Pharmaceuticals?

How do I contact Cyclacel Pharmaceuticals' investor relations team?

Cyclacel Pharmaceuticals' physical mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company's listed phone number is (908) 517-7330 and its investor relations email address is [email protected] The official website for Cyclacel Pharmaceuticals is www.cyclacel.com. Learn More about contacing Cyclacel Pharmaceuticals investor relations.